FrancophonIA/ELRC3.0 huggingface dataset:
English: Evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with Vectibix.
Croatian: Prije početka liječenja lijekom Vectibix potrebno je potvrditi status divljeg tipa RAS gena (KRAS i NRAS).
English: Seek medical attention immediately if you experience symptoms of an allergic reaction to Vectibix, including but not limited to difficulty breathing, chest tightness, a sensation of choking, dizziness, or fainting.
Croatian: Ovi simptomi uključuju, između ostalog, otežano disanje, stezanje u prsima, osjećaj gušenja, omaglicu ili nesvjesticu.
English: Onychoclasis
Croatian: Nuspojave
English: Response rate (investigator assessed)a (95% CI) Stable Disease PFS
Croatian: Stopa objektivnog odgovora (ORR) n (%) Stopa odgovora (prema procjeni ispitivača)a (95% CI)
English: • hair loss (alopecia); mouth ulcers and cold sores (stomatitis); inflammation of the mouth
Croatian: • gubitak kose (alopecija); ranice usne šupljine i herpes usne šupljine (stomatitis); upala sluznice usne šupljine;
English: Bronchospasm Nasal dryness
Croatian: Akneiformni dermatitis Osip
English: < 1% as detected by the acid-dissociation ELISA and 3.8% as detected by the Biacore assay;
Croatian: • Incidencija vežućih protutijela (isključujući bolesnike pozitivne prije primjene prve doze i prolazno pozitivne bolesnike) bila je < 1%, detektiranih kiselinsko-disocirajućim testom ELISA i 3,8% detektirano testom Biacore;
English: Hyperhidrosis
Croatian: Hipertenzija
English: Life-threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix.
Croatian: Kod bolesnika liječenih lijekom Vectibix opažene su komplikacije u obliku infekcija opasnih po život i sa smrtnim ishodom, uključujući nekrotizirajući fasciitis i sepsu.
English: Dose regulation
Croatian: Prilagodba doze
English: Rectal haemorrhage Dry mouth
Croatian: Rektalno krvarenje Suha usta Dispepsija Aftozni ulkus Heilitis
English: Hypokalaemia Hypomagnesaemia Decreased appetite
Croatian: Smanjeni apetit
English: EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells.
Croatian: I u koju se ubrajaju EGFR (HER1/c-ErbB-1), HER2, HER3 i HER 4. EGFR stimulira rast stanica u normalnim epitelnim tkivima, uključujući kožu i folikul dlake te je eksprimiran na stanicama različitih vrsta tumora.
English: Pruritus
Croatian: Tahikardija
English: Skin fissures Acne
Croatian: Fisure kože
English: Rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in patients treated with Vectibix in the post-marketing setting.
Croatian: U razdoblju nakon stavljanja lijeka u promet kod bolesnika liječenih lijekom Vectibix prijavljeni su rijetki slučajevi Stevens-Johnsonovog sindroma i toksične epidermalne nekrolize.
English: • nail disorder; breaking of the nails (onychoclasis);
Croatian: • poremećaj nokta; lomljivi nokti (onihoklazija);
English: Chest pain Pain
Croatian: Bol u prsištu Bol
English: Mucosal inflammation Oedema peripheral
Croatian: Iritacija očnog kapka
English: Strength Pharmaceutical Form Route of administration
Croatian: Doza Farmaceutski oblik Put primjene
English: 26 February 2015
Croatian: 26. veljače 2015.
English: Adopted at the 9-12 February 2015 PRAC
Croatian: Usvojeno na sjednici PRAC-a 9. - 12. veljače 2015.
English: Following the variations of the marketing authorisations for these products, the MAH for any product with the same active substance should submit a respective variation application.
Croatian: Nakon izmjena odobrenja za stavljanje u promet ovih lijekova, nositelj odobrenja za svaki lijek s istom djelatnom tvari treba podnijeti odgovarajući zahtjev za izmjenu.
English: Aripiprazole - Hyperprolactinaemia (EPITT no 18086)
Croatian: Aripiprazol - hiperprolaktinemija (EPITT br. 18086)
English: The package leaflets should be updated accordingly.
Croatian: Upute o lijeku treba ažurirati u skladu s tim.
English: Having considered the available evidence in EudraVigilance, the MAH's clinical trials and pharmacovigilance databases and the literature, the PRAC has agreed that the MAH of Abilify and Abilify Maintena should submit variations within 2 months, to amend the product information as described below (new text underlined).
Croatian: Nakon razmatranja dostupnih dokaza iz baze EudraVigilance, kliničkih ispitivanja i farmakovigilancijskih baza podataka nositelja odobrenja te literature, PRAC je zaključio da nositelj odobrenja za lijekove Abilify i Abilify Maintena treba podnijeti izmjene u roku od 2 mjeseca kako bi se izmijenile informacije o lijeku na način opisan u nastavku teksta (novi tekst je podcrtan).
English: PRAC recommendations on signals for update of the product information EMA/PRAC/118045/2015
Croatian: Preporuke PRAC-a vezane uz signale za ažuriranje informacija o lijeku EMA/PRAC/149176/2015
English: Feeling unwell, confused or weak, feeling sick (nausea), loss of appetite, feeling irritable.
Croatian: Vrlo rijetko (javljaju se kod manje od 1 na 10 000 osoba) Opće loše osjećanje, smetenost ili slabost, mučnina, gubitak apetita, osjećaj razdražljivosti.
English: This could be an illness called ‘syndrome of inappropriate anti-diuretic hormone secretion' (SIADH).
Croatian: To može biti bolest koja se naziva „sindrom neodgovarajućeg izlučivanja antidiuretskog hormona" (SIADH).
English: Having considered the available evidence the PRAC has agreed that the MAHs of amiodarone for intravenous administration should submit a variation within 2 months, to amend the product information as described below (new text underlined).
Croatian: Nakon razmatranja dostupnih dokaza, PRAC je zaključio da nositelji odobrenja za amiodaron za intravensku primjenu trebaju podnijeti izmjenu u roku od 2 mjeseca kako bi se izmijenile informacije o lijeku na način opisan u nastavku teksta (novi tekst je podcrtan).
English: Amiodarone - Syndrome of inappropriate antidiuretic hormone secretion (SIADH) (EPITT no 18091)
Croatian: Amiodaron - sindrom neodgovarajućeg izlučivanja antidiuretskog hormona (SIADH) (EPITT br. 18091)
English: In addition, the MAH should describe the data on hyper- and hypoprolactinaemia in the SmPCs' sections 5.1.
Croatian: Nadalje, nositelj odobrenja treba opisati podatke o hiperprolaktinemiji i hipoprolaktinemiji u dijelu 5.1. Sažetka opisa svojstava lijeka.
English: In clinical trials for the approved indication(s) and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).
Croatian: U kliničkim ispitivanjima za odobrenu(e) indikaciju(e) i nakon stavljanja lijeka u promet, s aripiprazolom je uočeno i povećanje i smanjenje razine prolaktina u serumu u odnosu na početnu vrijednost (dio 5.1.).
English: Frequency ‘uncommon': Hyperprolactinaemia
Croatian: Učestalost „manje često": Hiperprolaktinemija
English: Section 4: Possible side effects Uncommon side effects (may affect up to 1 in 100 people): Increased blood levels of the hormone prolactin.
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): Povišenje razine hormona prolaktina u krvi.
English: Very rare: Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Croatian: Vrlo rijetko: Sindrom neodgovarajućeg izlučivanja antidiuretskog hormona (SIADH)
English: Summary of product characteristics (SmPC) Section 4.8:
Croatian: Sažetak opisa svojstava lijeka Dio 4.8.
English: SmPC
Croatian: Nuspojave:
English: Powder for concentrate for solution for infusion
Croatian: 2 g/0,5 g prašak za koncentrat za otopinu za infuziju
English: EMA/618757/2017
Croatian: EMA/618757/2017 EMEA/H/C/004319
English: These packs will include information on the safety of the medicine.
Croatian: Ti će paketi uključivati informacije o sigurnosti lijeka.
English: What is Cyltezo and what is it used for?
Croatian: Što je Cyltezo i za što se koristi?
English: The full EPAR for Cyltezo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Cyltezo nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This compared with 61% and 65% of those given Humira.
Croatian: To se uspoređivalo sa 61 % odnosno 65 % bolesnika koji su dobivali lijek Humira.
English: The dose and frequency of injection depends on the condition to be treated and the dose for a child is calculated according to the child's weight and height.
Croatian: Doza i učestalost injekcije ovisi o stanju koje je potrebno liječiti, a doza za djecu izračunava se u skladu s težinom i visinom djeteta.
English: Treatment response was measured as a 20% or more improvement in symptom score, which was seen after 12 and 24 weeks of treatment in 67% and 69% respectively of those given Cyltezo.
Croatian: Odgovor na liječenje mjerio se kao poboljšanje zbroja simptoma od 20 % ili više, što je primijećeno nakon 12 i 24 tjedna liječenja u 67 % odnosno 69 % bolesnika koji su dobivali lijek Cyltezo.
English: This means that Cyltezo is highly similar to a biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU).
Croatian: Drugim riječima, lijek Cyltezo vrlo je sličan biološkom lijeku („referentni lijek”) koji je već odobren u Europskoj uniji (EU).
English: After training, patients or their carers may inject Cyltezo if their doctor considers it appropriate.
Croatian: Nakon obuke bolesnici ili njihovi njegovatelji mogu injektirati lijek Cyltezo ako to njihov liječnik smatra primjerenim.
English: This is a summary of the European public assessment report (EPAR) for Cyltezo.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) za lijek Cyltezo.
English: Cyltezo is a medicine that acts on the immune system and is used to treat the following conditions:
Croatian: Cyltezo je lijek koji djeluje na imunosni sustav te se koristi za liječenje sljedećih stanja:
English: The company that markets Cyltezo must provide educational packs for doctors who prescribe the medicine.
Croatian: Tvrtka koja stavlja na tržište lijek Cyltezo mora dostaviti edukacijske pakete za liječnike koji propisuju taj lijek.
English: Therefore, the Agency's view was that, as for Humira, the benefit outweighs the identified risk, and it recommended that Cyltezo be given marketing authorisation.
Croatian: Stoga je mišljenje Agencije da, kao i kod lijeka Humira, koristi nadmašuju identificirane rizike te je preporučila davanje odobrenja za stavljanje lijeka Cyltezo u promet.
English: Like other medicines of its class, Cyltezo may affect the ability of the immune system to fight off infections and cancer, and there have been some cases of serious infections and blood cancers in patients using adalimumab.
Croatian: Kao i drugi lijekovi u tom razredu, Cyltezo može utjecati na sposobnost imunosnog sustava da se bori protiv infekcija i raka, pa su zabilježeni slučajevi ozbiljnih infekcija i raka krvi u bolesnika koji su liječeni adalimumabom.
English: The reference medicine for Cyltezo is Humira.
Croatian: Referentni lijek za lijek Cyltezo je Humira.
English: What are the risks associated with Cyltezo?
Croatian: Koji su rizici povezani s lijekom Cyltezo?
English: Cyltezo is available as a solution for injection under the skin in a pre-filled syringe or pen and is usually given every 2 weeks.
Croatian: Cyltezo je dostupan kao otopina za potkožnu injekciju u napunjenoj štrcaljki ili brizgalici te se obično primjenjuje svaka dva tjedna.
English: Because Cyltezo is a biosimilar medicine, the studies on effectiveness and safety of adalimumab carried out with Humira do not all need to be repeated for Cyltezo.
Croatian: Budući da je lijek Cyltezo biosličan lijek, ispitivanja učinkovitosti i sigurnosti adalimumaba provedena za lijek Humira nije potrebno ponavljati za lijek Cyltezo.
English: Cyltezo must not be used in patients with active tuberculosis or other severe infections, or in patients with moderate to severe heart failure (an inability of the heart to pump enough blood around the
Croatian: Cyltezo se ne smije primjenjivati u bolesnika s aktivnom tuberkulozom ili drugim teškim infekcijama ni u bolesnika s umjerenim do teškim zatajenjem srca (nesposobnost srca da pumpa dovoljne količine
English: The active substance in Cyltezo, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF).
Croatian: Djelatna tvar u lijeku Cyltezo, adalimumab, monoklonsko je protutijelo (vrsta proteina) namijenjeno prepoznavanju i vezivanju za tvar u tijelu zvanu faktor tumorske nekroze (TNF).
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Cyltezo has a highly similar structure, purity and biological activity to Humira and is distributed in the body in the same way.
Croatian: Europska agencija za lijekove zaključila je da, u skladu sa zahtjevima EU-a za bioslične lijekove, lijek Cyltezo ima vrlo sličnu strukturu, čistoću i biološku aktivnost kao i lijek Humira te se u tijelu
English: Other rare serious side effects (which may affect up to 1 in 1,000 people) include failure of bone marrow to produce blood cells, disorder of the nerves, lupus and lupus-like conditions (where the immune system attacks the patient's own tissues, causing inflammation and organ damage), and Stevens-Johnson syndrome (a serious skin condition).
Croatian: Druge rijetke ozbiljne nuspojave (koje se mogu pojaviti u najviše 1 na 1 000 osoba) uključuju poremećaj u kojemu koštana srž više ne proizvodi krvne stanice, poremećaje živaca, lupus i poremećaje slične lupusu (pri čemu imunosni sustav bolesnika napada tkiva u vlastitom organizmu, uzrokujući upalu i oštećenja organa) i Stevens-Johnsonov sindrom (ozbiljnu bolest kože).
English: Cyltezo is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Croatian: Cyltezo se prvenstveno koristi u odraslih osoba kod ozbiljnog, umjereno ozbiljnog stanja bolesti ili onog koje se pogoršava, odnosno kad bolesnici ne mogu primiti drugu terapiju.
English: By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.
Croatian: Vezivanjem na TNF adalimumab inhibira njegovo djelovanje te tako smanjuje upalu i druge
English: Cyltezo contains the active substance adalimumab and is a ‘biosimilar medicine'.
Croatian: Cyltezo sadrži djelatnu tvar adalimumab te je „biosličan lijek”.
English: In addition, a study involving 645 patients with moderate or severe rheumatoid arthritis who were also taking methotrexate confirmed that Cyltezo and Humira have similar effectiveness.
Croatian: Osim toga, u ispitivanju u kojem je sudjelovalo 645 bolesnika s umjerenim ili teškim reumatoidnim artritisom pokazalo se da su unatoč liječenju metotreksatom lijekovi Cyltezo i Humira imali sličnu djelotvornost.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cyltezo have also been included in the summary of product characteristics and the
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Cyltezo nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Treatment with Cyltezo must be started and supervised by a doctor who has experience in the treatment of the diseases for which Cyltezo is used.
Croatian: Liječenje lijekom Cyltezo mora započeti i nadzirati liječnik s iskustvom u liječenju bolesti za koje se Cyltezo koristi.
English: For detailed information on the use of Cyltezo in all conditions, including when it can be used in children, see the summary of product characteristics.
Croatian: Detaljne informacije o primjeni lijeka Cyltezo za sva stanja, kao i kada se može primjenjivati u djece, potražite u sažetku opisa svojstva lijeka.
English: It is not intended to provide practical advice on how to use Cyltezo.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Cyltezo.
English: Cyltezo can only be obtained by prescription.
Croatian: Cyltezo se izdaje samo na liječnički recept.
English: • axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation;
Croatian: • aksijalnog spondiloartritisa (upale kralježnice koja uzrokuje bolove u leđima), kao i ankilozantnog spondilitisa te kad rendgenska snimka ne pokazuje bolest, no postoje jasni znaci upale;
English: TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Cyltezo is used to treat.
Croatian: TNF je uključen u nastajanje upale i pronađen je u velikim koncentracijama u bolesnika s bolestima koje se liječe lijekom Cyltezo.
English: What benefits of Cyltezo have been shown in studies?
Croatian: Koje su koristi lijeka Cyltezo dokazane u ispitivanjima?
English: An alert card will also be
Croatian: Bolesnici će također dobiti karticu s
English: For more information about treatment with Cyltezo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Cyltezo pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svom liječniku ili
English: All these data were considered sufficient to conclude that Cyltezo will behave in the same way as Humira in terms of effectiveness and safety in its approved uses.
Croatian: Svi ti podatci smatraju se dovoljnima za donošenje zaključka da će lijek Cyltezo za odobrene indikacije djelovati na isti način kao lijek Humira u pogledu djelotvornosti i sigurnosti.
English: Laboratory studies comparing Cyltezo with Humira have shown that the active substance in Cyltezo is highly similar to that in Humira in terms of structure, purity and biological activity.
Croatian: Laboratorijska ispitivanja u kojima su uspoređivani lijekovi Cyltezo i Humira pokazala su da je djelatna tvar u lijeku Cyltezo vrlo slična djelatnoj tvari u lijeku Humira u pogledu strukture, čistoće i biološke aktivnosti.
English: • polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases
Croatian: • poliartikularnog juvenilnog idiopatskog artritisa i aktivnog artritisa povezanog s entezitisom (obje su rijetke bolesti koje uzrokuju upalu zglobova);
English: Comparable benefit continued to be seen with longer term
Croatian: Usporedive koristi od lijeka zabilježene su i pri dugoročnijem liječenju u trajanju od 48 tjedana.
English: In addition, a study in rheumatoid arthritis has shown that the effects of the medicine are equivalent to those of Humira in this condition.
Croatian: Nadalje, u ispitivanju reumatoidnog artritisa utvrđeno je da je djelotvornost tog lijeka jednaka djelotvornosti lijeka Humira pri liječenju tih stanja.
English: Studies have also shown that giving Cyltezo produces similar levels of the active substance in the body to giving Humira.
Croatian: Ispitivanja su dokazala i da primjena lijeka Cyltezo dovodi do slične razine djelatne tvari u tijelu kao i primjena lijeka Humira.
English: • Crohn's disease (a disease causing inflammation of the gut);
Croatian: • Crohnove bolesti (bolesti koja uzrokuje upalu crijeva);
English: • plaque psoriasis (a disease causing red, scaly patches on the skin);
Croatian: • plak psorijaze (bolesti koja uzrokuje crvene ljuskave lezije na koži);
English: For the full list of side effects and restrictions with Cyltezo, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Cyltezo potražite u uputi o lijeku.
English: • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);
Croatian: • ulceroznog kolitisa (bolesti koja uzrokuje upalu i čireve na stijenci crijeva);
English: Doctors treating uveitis should also take advice from doctors who have experience of using Cyltezo.
Croatian: Liječnici koji liječe uveitis trebali bi također poslušati savjete liječnika s iskustvom u
English: For practical information about using Cyltezo, patients should read the package leaflet or contact their
Croatian: Praktične informacije o primjeni lijeka Cyltezo bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: • psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints);
Croatian: • psorijatičnog artritisa (bolesti koja uzrokuje crvene ljuskave lezije na koži i upalu zglobova);
English: For example,
Croatian: Na primjer,
English: Do not give this medicine to children and adolescents (under 18 years of age).
Croatian: Nemojte davati ovaj lijek djeci i adolescentima (mlađima od 18 godina).
English: This can be seen in a blood test;
Croatian: Ovo se može vidjeti putem krvnih pretraga;
English: • make your treatment ineffective and your tuberculosis could get worse, and;
Croatian: • liječenje može biti neučinkovito i tuberkuloza Vam se može pogoršati, i;
English: The following definitions applies for resistance categories used:
Croatian: Sljedeće se definicije primjenjuju za kategorije rezistencije:
English: First 2 weeks:
Croatian: Prva 2 tjedna:
English: From week 3 to week 24:
Croatian: Od tjedna 3 do tjedna 24:
English: you may take SIRTURO on Monday, Wednesday and Friday every week from week 3
Croatian: SIRTURO možete uzimati ponedjeljkom, srijedom i petkom svaki tjedan od tjedna 3 pa nadalje.
English: Table 1: Culture conversion Status
Croatian: Tablica 1: Status konverzije kulture
English: The recommended dosage is:
Croatian: Preporučeno doziranje je:
English: This is because it has not been studied in this age group.
Croatian: To je zbog toga jer nije ispitan u ovoj starosnoj skupini.
English: The food is important to get the right levels of medicine in your body.
Croatian: Hrana je važna radi postizanja prave razine lijeka u Vašem tijelu.
English: You may need to keep taking your other medicines for tuberculosis for longer than 6 months.
Croatian: Možda ćete morati nastaviti uzimati druge lijekove za tuberkulozu duže od 6 mjeseci.
English: It is used in adults aged 18 years and over.
Croatian: Koristi se u odraslih u dobi od 18 godina i starijih.
English: Culture Conversion Status, n (%)
Croatian: Status pretvorbe kulture, n (%)
English: Data on longer treatment duration is very limited.
Croatian: Podaci o dužem trajanju liječenja su vrlo ograničeni.
English: 188 tablets
Croatian: 188 tableta
English: The most common cause of death as reported by the investigator was tuberculosis (9 patients).
Croatian: Najčešći razlog smrti prema prijavama ispitivača bila je tuberkuloza (9 bolesnika).
English: All of these toxicities except effects on MPS were monitored clinically.
Croatian: Sve ove toksičnosti osim učinaka na MPS nadzirale su se klinički.
English: S = susceptible R = resistant
Croatian: S = osjetljiv R = rezistentan
English: • you have liver disease or you drink alcohol on a regular basis;
Croatian: • ako imate bolest jetre ili redovito pijete alkohol;
English: If this happens do not drive or operate machinery.
Croatian: Ako se to dogodi nemojte upravljati vozilima ili strojevima.
English: The causes of death in the remaining patients varied.
Croatian: Razlozi smrti kod preostalih bolesnika bili su raznoliki.
English: Clinical monitoring should be considered.
Croatian: Mora se razmotriti kliničko praćenje.
English: Your doctor will decide which other medicines you should take with SIRTURO.
Croatian: Vaš liječnik će odlučiti koje druge lijekove morate uzimati s lijekom SIRTURO.
English: A final evaluation was conducted at Week 120.
Croatian: Završna procjena provedena je u 120. tjednu.
English: • Resume the three times a week schedule.
Croatian: • Nastavite s rasporedom uzimanja tri puta na tjedan.
English: After treatment cessation, all indications of toxicity exhibited at least partial recovery to good recovery.
Croatian: Nakon ukidanja liječenja, sve naznake toksičnosti pokazale su barem djelomičan do dobar oporavak.